EyePoint to Present at Guggenheim SMID Cap Biotech Conference

Rhea-AI Summary

EyePoint Pharmaceuticals (NASDAQ: EYPT), a company focused on developing therapeutics for serious retinal diseases, has announced its upcoming participation in the Guggenheim SMID Cap Biotech Conference. Jay S. Duker, M.D., the company's President and CEO, will engage in a fireside chat scheduled for Thursday, February 6, 2025, at 9:30 a.m. ET.

Interested parties can access the webcast and subsequent replay through the Investors section of EyePoint's website at www.eyepointpharma.com.

WATERTOWN, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that Jay S. Duker, M.D., President and Chief Executive Officer of EyePoint will participate in a fireside chat at the Guggenheim SMID Cap Biotech Conference on Thursday, February 6, 2025 at 9:30 a.m. ET.

A webcast and subsequent archived replay of the fireside chat may be accessed via the Investors section of the Company website at www.eyepointpharma.com.

About EyePoint Pharmaceuticals

EyePoint (Nasdaq: EYPT) is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative therapeutics to help improve the lives of patients with serious retinal diseases. The Company's pipeline leverages its proprietary bioerodible Durasert E^™ technology for sustained intraocular drug delivery. The Company’s lead product candidate, DURAVYU^™ (f/k/a EYP-1901), is an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with bioerodible Durasert E^™. DURAVYU is presently in Phase 3 global, pivotal clinical trials as a sustained delivery treatment for wet age-related macular degeneration (wet AMD), the leading cause of vision loss among people 50 years of age and older in the United States, and in a Phase 2 clinical trial in diabetic macular edema (DME). EyePoint expects full topline data from the Phase 2 clinical trial in DME in Q1 2025 and topline data from both Phase 3 pivotal trials in wet AMD in 2026.

Pipeline programs include EYP-2301, a TIE-2 agonist, razuprotafib, formulated in Durasert E^™ to potentially improve outcomes in serious retinal diseases. The proven Durasert^® drug delivery technology has been safely administered to thousands of patient eyes across four U.S. FDA approved products. EyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts.

Vorolanib is licensed to EyePoint exclusively by Equinox Sciences, a Betta Pharmaceuticals affiliate, for the localized treatment of all ophthalmic diseases outside of China, Macao, Hong Kong and Taiwan.

DURAVYU™ has been conditionally accepted by the FDA as the proprietary name for EYP-1901. DURAVYU is an investigational product; it has not been approved by the FDA. FDA approval and the timeline for potential approval is uncertain.

Investors:

Christina Tartaglia
Precision AQ
Direct: 212-698-8700
christina.tartaglia@precisionaq.com

Media Contact:

Amy Phillips
Green Room Communications
Direct: 412-327-9499
aphillips@greenroompr.com

FAQ

When is EyePoint Pharmaceuticals (EYPT) presenting at the Guggenheim SMID Cap Biotech Conference?

EyePoint Pharmaceuticals will present at the Guggenheim SMID Cap Biotech Conference on Thursday, February 6, 2025, at 9:30 a.m. ET.

How can investors watch EyePoint's (EYPT) Guggenheim Conference presentation?

Investors can watch the webcast and access the replay through the Investors section of EyePoint's website at www.eyepointpharma.com.

Who will represent EyePoint Pharmaceuticals (EYPT) at the Guggenheim SMID Cap Biotech Conference?

Jay S. Duker, M.D., President and Chief Executive Officer of EyePoint Pharmaceuticals, will represent the company in a fireside chat.

What type of presentation will EyePoint (EYPT) give at the Guggenheim Conference?

EyePoint will participate in a fireside chat format presentation at the conference.